ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.

ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) ...